| Prognosis | Certain mutations are associated with more rapid progression |
| Progressive Supranuclear Palsy (PSP) | Strong association with MAPT (microtubule-associated protein tau) H1 haplotype, accounting for ~40% of genetic risk |
| Multiple System Atrophy (MSA) | Associated with SNCA (alpha-synuclein) variants, GBA (glucocerebrosidase) mutations, and COQ2 variants |
| Corticobasal Degeneration (CBD) | MAPT mutations and H1 haplotype are major genetic risk factors |
| Differential diagnosis | Genetic signatures can help distinguish between PSP, MSA, CBD, and PD |
| Family counseling | Identifies at-risk family members |
| Therapeutic trials | Genetic stratification for clinical trials |
| Tau-targeted therapies | Antisense oligonucleotides and small molecules targeting tau for PSP and CBD |
| Alpha-synuclein aggregation inhibitors | Being developed for MSA |
| Neuroprotective strategies | Based on understanding of genetic risk pathways |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!